Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.  The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera), for patients who have not previously been treated for HIV.  It is available as a once-a-day single tablet.
Emtricitabine rilpivirine tenofovir
Elvitegravir cobicistat emtricitabine tenofovir
Abacavir lamivudine
Lopinavir ritonavir
Dolutegravir / rilpivirine
Ledipasvir / sofosbuvir
Bictegravir / emtricitabine / tenofovir alafenamide
Sofosbuvir / velpatasvir